Every Form 4 that Avalyn Pharma Inc. (AVLN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVLN filings page.
Avalyn Pharma Inc. (AVLN) reported that director Robert J. Meyer received a stock option award on September 15, 2026. The option covers 31,182 shares of common stock at an exercise price of $34.28 per share, expiring on September 14, 2036. The option vests in three equal annual installments after the grant date, conditioned on his continued service.
Novo Holdings A/S, a more than 10% owner of Avalyn Pharma Inc., reported a combination of open-market buying and preferred stock conversions into common shares. On May 1, 2026, Novo bought 555,555 shares of Avalyn voting common stock in the open market at $18.00 per share, bringing its direct common stock holdings to 3,883,289 shares after the purchase.
On the same date, multiple series of Avalyn preferred stock held by Novo automatically converted into voting common stock upon the closing of Avalyn’s initial public offering for no additional consideration. According to the filing, the Series A, B, C-1, C-2 and D Preferred Stock converted into voting common stock on a 1-for-19.2417 basis and had no expiration date. Following these conversions, the preferred stock positions reported in the filing show zero remaining shares.
Avalyn Pharma Inc. reported that SR One Capital Fund II Aggregator, LP, an entity associated with director Jill Carroll, made several equity transactions in connection with the company’s initial public offering. On May 1, 2026, the entity completed an open-market purchase of 277,778 shares of Common Stock at $18.00 per share, bringing its indirect Common Stock holdings to 2,186,562 shares after that trade. On the same date, all of its Series C-1 and Series D Convertible Preferred Stock automatically converted into Common Stock at a one-for-19.2417 ratio immediately prior to the IPO closing, eliminating those preferred positions and resulting in additional Common Stock holdings. Carroll is affiliated with the SR One entities and disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Avalyn Pharma Inc. director Heather D. Turner received a compensation grant of stock options covering 26,978 shares of common stock. The options have an exercise price of $18.00 per share and expire on April 28, 2036.
According to the vesting terms, 25% of the shares vest and become exercisable on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to her continued service. Following this grant, Turner holds stock options for 26,978 underlying shares directly.
Avalyn Pharma Inc. reported that its Chief Financial Officer, Douglas R. Carlson, received a grant of stock options covering 211,975 shares of Common Stock. These options have an exercise price of $18.0000 per share and expire on April 28, 2036.
According to the vesting schedule, 25% of the shares vest and become exercisable on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments, conditioned on his continued service. Following this award, he holds 211,975 derivative securities linked to Avalyn Pharma stock.
Avalyn Pharma Inc. director Kate Haviland received a new stock option grant covering 26,978 shares of common stock. The option has an exercise price of $18.00 per share and expires on April 28, 2036.
This award is compensation-related, not an open-market trade. According to the vesting terms, 25% of the shares underlying the option vest on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to her continued service. Following this grant, she holds 26,978 stock options directly from this award.
Wellington Biomedical Innovation Master Investors (Cayman) II L.P., a 10% owner of Avalyn Pharma Inc., reported converting its preferred stock into common shares. On May 1, 2026, it acquired 1,275,486 shares of Common Stock through the automatic conversion of Series C-1 and Series D Convertible Preferred Stock immediately prior to Avalyn’s initial public offering. Following these transactions, the reporting holder’s remaining position consists of common stock, with the preferred stock fully converted.
Avalyn Pharma director Erin Lavelle received a grant of stock options covering 26,978 shares of common stock at an exercise price of $18.00 per share. Twenty-five percent vest on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.